Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of DVS-233 SR in Major Depressive Disorder
NCT00073762Phase 3Completed
- Sponsor
- Pfizer
- Primary completion
- Sep 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of desvenlafaxine in major depressive disorder (MDD) (3 arms), sponsored by Pfizer. Primary endpoint: Antidepressant Efficacy (likely HAM-D17). Status: completed.
02
Drugs
desvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00073762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00073762.